ArticleBMC oral health2026
Cold atmospheric plasma for implant surface decontamination and osseointegration: a scoping review with implications for peri-implantitis management.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeri-implantitis is a biofilm-associated inflammatory condition leading to progressive bone loss around dental implants. Effective management requires both implant surface decontamination and re-establishment of osseointegration. Cold atmospheric plasma (CAP) has emerged as a promising approach due to its antimicrobial activity and its ability to modify implant surface properties.
methodsThis scoping review was conducted in accordance with the PRISMA-ScR guidelines. A comprehensive search of PubMed, Scopus, Web of Science, and Google Scholar was performed to identify relevant studies. In vitro, ex vivo, and animal studies investigating the effects of CAP on implant surface decontamination and/or osseointegration were included. Given the limited availability of standardized peri-implantitis models, studies reflecting key biological components of the disease process were considered.
resultsA total of 77 studies were included. Among them, 31 focused on implant surface decontamination and 46 evaluated osseointegration-related outcomes. The included studies were highly heterogeneous in terms of plasma devices, gas composition, exposure parameters, implant materials, and biological models. Overall, CAP demonstrated consistent antibacterial effects and was associated with improved surface hydrophilicity, enhanced osteoblast response, and increased bone-to-implant contact in preclinical settings.
conclusionsCAP appears to possess a dual potential to support implant surface decontamination and osseointegration-related processes, targeting biological processes relevant to peri-implantitis. However, the evidence is largely preclinical and derived from heterogeneous models that do not uniformly reproduce the clinical condition of peri-implantitis. Therefore, current findings support the biological plausibility of CAP as an adjunctive strategy, while its clinical effectiveness and optimal application protocols remain to be established through well-designed in vivo studies and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.